A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Brilacidin (Primary) ; Daptomycin
Indications Abscess; Methicillin-resistant Staphylococcus aureus infections; Post-traumatic infections; Postoperative infections; Skin and soft tissue infections; Staphylococcal infections; Streptococcal infections; Wound infections
Focus Therapeutic Use
Sponsors Cellceutix

30 Oct 2015 According to Cellceutix media release, company had a positive end-of-phase 2 meeting with the FDA in July 2015.
30 Oct 2015 Results published in Cellceutix media release.
21 Sep 2015 Results assessing population pharmacokinetics presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com